Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

This phase I trial studies the side effects and best dose of modified immune cells (IL13Ralpha2 CAR T cells) after a chemotherapy conditioning regimen for the treatment of patients with stage IIIC or IV melanoma or solid tumors that have spread to other places in the body (metastatic). The study agent is called IL13Ralpha2 CAR T cells. T cells are a special type of white blood cell (immune cells) that have the ability to kill tumor cells. The T cells are obtained from the patient's own blood, grown in a laboratory, and modified by adding the IL13Ralpha2 CAR gene. The IL13Ralpha2 CAR gene is in

Trial Details

NCT ID
NCT04119024
Phase
PHASE1
Sponsor
Anusha Kalbasi
Status
RECRUITING
Cancer Type
Melanoma
Interventions
  • Biopsy
  • Biospecimen Collection
  • Computed Tomography
  • Cyclophosphamide
  • Fludarabine Phosphate
  • Fludeoxyglucose F-18
Locations (sample)
  • Duarte, California, United States|34.13945,-117.97729
  • Los Angeles, California, United States|34.05223,-118.24368
  • Stanford, California, United States|37.42411,-122.16608

Key Eligibility Criteria

  • Histologically confirmed malignancy that is considered surgically incurable with either:
  • Stage IIIC melanoma including locally relapsed, satellite, in-transit lesions or bulky draining node metastasis
  • Stage IV melanoma including patients with known brain metastases
  • Other metastatic, non-central nervous system (CNS) solid tumor relapsed or refractory after all standard-of-care systemic therapies for which the p…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →